Adalimumab (brand name Humira) is a biologic DMARD that targets tumor necrosis factor-alpha (TNF-α), a key driver of inflammation in rheumatoid arthritis. It is given as a subcutaneous injection, usually every other week, and is often prescribed when patients have moderate to severe RA that does not respond well to methotrexate or other conventional DMARDs. Adalimumab can significantly reduce joint pain, swelling, and long-term damage, while improving function and quality of life. Common side effects include injection-site reactions and increased risk of infections (like tuberculosis or shingles), so patients require screening and ongoing monitoring. Despite its high cost, it is one of the most widely used biologics because of its strong track record of efficacy.